U.S. Markets closed

Hyperion Therapeutics initiates THRIVE study for urea cycle disorders

Hyperion Therapeutics has begun enrolling patients in its THRIVE study, a long term registry of patients with urea cycle disorders which will capture clinical outcomes and comparative effectiveness data. The study will track long-term outcomes, including hyperammonemic crises, ammonia levels, growth and development, and neurocognitive outcomes. Eligible patients will be enrolled in the study and followed for up to 10 years with annual interim data reports planned.